Swiss Franc To Fall Off Record Highs In 2024
Country Risk / Switzerland / Tue 09 Jan, 2024
2023 | Spot | 2024f | 2025f | |
CHF per USD, eop | 0.84 | 0.85 | 0.90 | 0.93 |
CHF per EUR, eop | 0.93 | 0.93 | 1.01 | 1.04 |
Policy Rate, % eop | 1.75 | 1.75 | 1.50 | 1.00 |
Country Risk / Switzerland / Tue 09 Jan, 2024
2023 | Spot | 2024f | 2025f | |
CHF per USD, eop | 0.84 | 0.85 | 0.90 | 0.93 |
CHF per EUR, eop | 0.93 | 0.93 | 1.01 | 1.04 |
Policy Rate, % eop | 1.75 | 1.75 | 1.50 | 1.00 |
Oil & Gas / China / Tue 09 Jan, 2024
Key View
Consumer & Retail / Saudi Arabia / Tue 09 Jan, 2024
Key View: We forecast real household spending in Saudi Arabia to normalise in 2024 as spending returns to a more steady growth trajectory. We expect the positive outlook in non-oil activity, through Vision 2030, and expected interest rate cuts in Q224 to support the wider economic recovery and consumer spending in 2024. There are downside risks
Agribusiness / Europe / Tue 09 Jan, 2024
Key View
Telecommunications / United Arab Emirates / Tue 09 Jan, 2024
Key View
Food & Drink / South Africa / Tue 09 Jan, 2024
The Latest: On October 26 2023, leading South African food manufacturer, Tiger Brands, launched a ready-to-drink (RTD) Jungle Oat Drink range. The new Jungle Oats RTD range is marketed as a functional breakfast or snack and will come in five flavours, each offering different functional benefits: Original – heart health, Banana – brain function
Pharmaceuticals / United States / Tue 09 Jan, 2024
The Latest: On December 21 2023, a letter sent to House Budget Committee Chair Jodey Arrington (R-TX) and Michael Burgess (R-TX) reported that the Congressional Budget Office (CBO) anticipates pharmaceutical companies will increase list prices for new drugs while simultaneously offering larger rebates in response to policies found within the
Telecommunications / Turkey / Mon 08 Jan, 2024
Key View
Telecommunications / Australia / Mon 08 Jan, 2024
Key View
Pharmaceuticals / Malaysia / Mon 08 Jan, 2024
The Latest: On January 4 2023, Roche achieved a significant milestone by initiating its pioneering first-in-human (FIH) clinical trials for a rheumatology indication in Malaysia. This marks Malaysia as the first market within the Asia-Pacific region to participate in such studies and positions Malaysia as the seventh global participant in Roche's